scilogo.jpg
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
August 01, 2022 09:30 ET | SciSparc Ltd
The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE)...
scilogo.jpg
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
July 08, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
scilogo.jpg
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
July 07, 2022 08:30 ET | SciSparc Ltd
The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a...
scilogo.jpg
SciSparc Board of Directors to Promote Buyback Program of up to $1 Million
July 06, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
June 29, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
June 23, 2022 09:30 ET | SciSparc Ltd
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
Logo.png
Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference
May 19, 2022 08:30 ET | Vyant Bio, Inc.
Cherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
Logo.png
Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021
March 28, 2022 16:30 ET | Vyant Bio, Inc.
CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
VistaGen logo FINAL.png
VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
March 24, 2022 08:00 ET | VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to...
logo.jpg
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
February 14, 2022 16:15 ET | Vallon Pharmaceuticals Inc.
- Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with...